Why Clinical Modulation of Efflux Transport at the Human Blood–Brain Barrier Is Unlikely: The ITC Evidence‐Based Position

Publisher： John Wiley & Sons Inc

E-ISSN： 1532-6535|94|1|80-94

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.94, Iss.1, 2013-07, pp. : 80-94

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mechanism of polymeric nanoparticle-based drug transport across the blood-brain barrier (BBB)

By Kreuter Jörg  

Journal of Microencapsulation, Vol. 30, Iss. 1, 2013-02 ,pp. : 49-54

Informa Healthcare

Access to resources Recommend Favorite

Profiling Solute Carrier Transporters in the Human Blood–Brain Barrier

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 94, Iss. 6, 2013-12 ,pp. : 636-639

John Wiley & Sons Inc

Access to resources Recommend Favorite

Endocannabinoids modulate human blood–brain barrier permeability in vitro

By  

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 172, Iss. 12, 2015-06 ,pp. : 3015-3027

John Wiley & Sons Inc

Access to resources Recommend Favorite

Blood–brain barrier: An impediment to neuropharmaceuticals

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 97, Iss. 4, 2015-04 ,pp. : 308-313

John Wiley & Sons Inc

Access to resources Recommend Favorite

Brain targeting PBCA nanoparticles and the blood––brain barrier

By Wilson B  

Nanomedicine, Vol. 4, Iss. 5, 2009-07 ,pp. : 499-502

Future Medicine

Access to resources Recommend Favorite